Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Retained Earnings: 2019-2024

Historic Retained Earnings for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to -$3.1 billion.

  • BridgeBio Pharma's Retained Earnings fell 28.15% to -$3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 billion, marking a year-over-year decrease of 28.15%. This contributed to the annual value of -$3.1 billion for FY2024, which is 20.92% down from last year.
  • As of FY2024, BridgeBio Pharma's Retained Earnings stood at -$3.1 billion, which was down 20.92% from -$2.6 billion recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Retained Earnings peaked at -$888.8 million during FY2020, and registered a low of -$3.1 billion during FY2024.
  • For the 3-year period, BridgeBio Pharma's Retained Earnings averaged around -$2.5 billion, with its median value being -$2.6 billion (2023).
  • Data for BridgeBio Pharma's Retained Earnings shows a maximum YoY slumped of 101.98% (in 2020) over the last 5 years.
  • Over the past 5 years, BridgeBio Pharma's Retained Earnings (Yearly) stood at -$888.8 million in 2020, then plummeted by 61.68% to -$1.4 billion in 2021, then plummeted by 33.49% to -$1.9 billion in 2022, then slumped by 33.49% to -$2.6 billion in 2023, then decreased by 20.92% to -$3.1 billion in 2024.